About

TFDA Approves Shiner's Phenbuty phase 4 clinical trial protocol.

Shiner Miaoli Zhunan Plant obtains Japan Foreign Manufacturer Accreditation.

Shiner Warehouse II obtains Japan Foreign Manufacturer Registration.

Epistatus 10 mg oromucosal solution receives TFDA approval of the specific medicinal products' importing as a special case.

Shiner's Permethrin 5% w/w Cream receives TFDA approval of the specific medicinal products' manufacturing as a special case.

secured medical device business permits.

TFDA gives green light to clinical trial protocol for Shiner's new drug.

Shiner has inked a deal with a Swiss company for a spray-type medication targeting chemotherapy-induced oral mucositis.

Shiner announces our inclusion in the reference list of biopharmaceutical industry research and development service companies.

Shiner Zhunan Plant obtains the PIC/S GMP certification from TFDA.

Shiner's MetaCu Capsules 300mg receives TFDA approval.

Shiner is entrusted with the development of a NCE for a tumor-related project.

Shiner Zhunan Plant underwent an on-site inspection conducted by TFDA.

Shiner enters into an exclusive supply and distribution agreement with a Dutch company for Class I medical products in the field of dermatology.

Shiner Zhunan Plant is officially registered, and it's been recognized with a Green Building certification.

Shiner signed an exclusive supply and distribution contract with a European company for orphan drugs.

Shiner has taken on the project of developing a NCE for neurodegenerative diseases.

Shiner announces a strategic partnership with a Swiss company for an innovative new ingredient in food products.

Shiner's Reosteo 150mg Tablets receives TFDA approval.

Shiner reveals our exclusive supply and distribution agreement with a Spanish company for rare disease medicinal products.

In a significant move, we've established a center of pharmaceutical development in Xizhi, New Taipei City, Taiwan.

Shiner obtains the necessary building permit to commence construction of a Western pharmaceutical formulation plant in the Hsinchu Science Park.

Shiner's pms-Methylphenidate ER 18mg Tablets receives TFDA approval.

Shiner's Phenbuty 500mg Tablets receives TFDA approval.

Shiner's pms-Methylphenidate ER 36mg Tablets receives TFDA approval.

Shiner receives approval and plans to establish a formulation plant in Hsinchu Science Park Zhunan Campus.

L-Carnit "Shiner" Injection 1g/5ml receives TFDA approval.

Shiner's Shilifil 100mg F.C. Tablets receives TFDA approval for the treatment of erectile dysfunction.

Shiner's "GelX" Oral Gel (Non-sterile) receives TFDA approval.

Shiner's Haxasin XL Tablets 4mg receives TFDA approval.

Shiner signs the agreement with Australian biopharmaceutical company for marketing a new HIV treatment.

Shiner's Pantopro Gastro-Resistant Tablets 40mg receives TFDA approval.

Shiner's Reosteo 35mg Tablets receives TFDA approval.

Exclusive Supply and Distribution Contract Signed with an Italian Company for Chemotherapy-Induced Oral Mucositis Products.

Shiner signs the agreement with a Canadian company for endocrine products and exclusive supply and distribution.

The collection of Hanlosin S.R.O.D. Tablets 0.2 mg.

Establishment of Shiner Pharm Corp.